AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis

Hongli Zhao, Jue Zhao, Jiapeng Hou, Siqing Wang, Yu Ding, Boxun Lu, Jian Wang

PDF(419 KB)
PDF(419 KB)
Protein Cell ›› 2017, Vol. 8 ›› Issue (9) : 696-700. DOI: 10.1007/s13238-017-0424-4
LETTER
LETTER

AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis

Author information +
History +

Cite this article

Download citation ▾
Hongli Zhao, Jue Zhao, Jiapeng Hou, Siqing Wang, Yu Ding, Boxun Lu, Jian Wang. AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis. Protein Cell, 2017, 8(9): 696‒700 https://doi.org/10.1007/s13238-017-0424-4

References

[1]
AaslyJO, JohansenKK, BronstadG, WaroBJ, MajbourNK, VargheseS, AlzahmiF, PaleologouKE, AmerDA, Al-HayaniA, El-AgnafOM (2014) Elevated levels of cerebrospinal fluid alphasynuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.Front Aging Neurosci6:248
CrossRef Google scholar
[2]
BartelsT, ChoiJG, SelkoeDJ (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation.Nature477(7362):107–110
CrossRef Google scholar
[3]
BerrocalR, VasquezV, KrsSR, GadadBS, KsR (2014) α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson’s Disease: Critical Assessment and Modeling.Molecular Neurobiology51(3):1417–1431
CrossRef Google scholar
[4]
BidinostiM, ShimshekDR, MollenhauerB, MarcellinD, SchweizerT, LotzGP, SchlossmacherMG, WeissA (2012) Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.Journal of Biological Chemistry287(40):33691–33705
CrossRef Google scholar
[5]
Bielefeld-SevignyM (2009) AlphaLISA immunoassay platform- the “no-wash” high-throughput alternative to ELISA.Assay Drug Dev Technol7(1):90–92
CrossRef Google scholar
[6]
De GenstEJ, GuilliamsT, WellensJ, O’DayEM, WaudbyCA, MeehanS, DumoulinM, HsuS-TD, CremadesN, VerschuerenKHG, PardonE, WynsL, SteyaertJ, ChristodoulouJ, DobsonCM (2010) Structure and Properties of a Complex of α-Synuclein and a Single-Domain Camelid Antibody.Journal of Molecular Biology402(2):326–343
CrossRef Google scholar
[7]
DelenclosM, JonesDR, McLeanPJ, UittiRJ (2016) Biomarkers in Parkinson’s disease: Advances and strategies.Parkinsonism Relat Disord22(Suppl 1):S106–S110
CrossRef Google scholar
[8]
El-AgnafOMA (2003) α-Synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma.FASEB J17(13):1945–1947
CrossRef Google scholar
[9]
KimD, PaikJH, ShinD-W, KimH-S, ParkC-S, KangJ-H (2014) What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson’s disease? Is the Significance Diagnostic or Prognostic?Experimental Neurobiology23(4):352
CrossRef Google scholar
[10]
LandeckN, HallH, ArdahMT, MajbourNK, El-AgnafOM, HallidayG, KirikD (2016) A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alphasynuclein.Mol Neurodegener11(1):61
CrossRef Google scholar
[11]
MajbourNK, VaikathNN, van DijkKD, ArdahMT, VargheseS, VesteragerLB, MontezinhoLP, PooleS, Safieh-GarabedianB, TokudaT, TeunissenCE, BerendseHW, van de BergWD, El-AgnafOM (2016) Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease.Mol Neurodegener11:7
CrossRef Google scholar

RIGHTS & PERMISSIONS

2017 The Author(s) 2017. This article is an open access publication
AI Summary AI Mindmap
PDF(419 KB)

Accesses

Citations

Detail

Sections
Recommended

/